To the Editor, I want to congratulate Patel et al. [1] for their study. They evaluated oncologic outcomes and toxicities for pre-stereotactic radiosurgery (SRS) (pre-SRS) and post-operative whole brain radiation therapy (WBRT) (post-WBRT) for resectable brain metastases (BM). They concluded that pre-SRS is a viable alternative to post-WBRT for resected BM. Comparing patients characterstics, some tumor types are not equally distributed in both arms (lung cancer 47.2 and 36.4%, melanoma 5.6 and 16.7% in post-WBRT and pre-SRS, respectively). Outcome of these tumor types with BM may differ. Secondly, though breast cancer BM are distributed equally in both arms, breast cancer HER-2 positive tumor subtype may show better outcome compared to triple negative breast cancer [2] . Therefore, description of breast tumor subtypes may better define the outcome in both arms. Finally, the authors did not give detailed information about the extension of extracranial metastases (bone
